Please note that the details of this Challenge are no longer open. This challenge is withdrawn and is no longer accepting new submissions. You can:
Challenge Novo Nordisk Challenge: Design and Synthesis of a Small Molecule Glucose Binder
Novo Nordisk Challenge: Design and Synthesis of a Small Molecule Glucose Binder
Award:  $200,000 USD
Deadline: Withdrawn
Active Solvers: 297
Posted: Mar 30 2016
Challenge ID: 9933823
 
Team Project Rooms are available on this Challenge. Team Share Challenge Share
Abstract

The control of glucose levels in the body is key for successful treatment of many disease states such as diabetes. Hence, Novo Nordisk is looking for novel small molecules that can bind with affinities matching the physiological concentrations of D-glucose (displacement constant, Kd, in the low millimolar range). 

This is a Reduction-to-Practice Challenge that requires written documentation, experimental proof-of-concept data, and sample delivery. Additionally, the Challenge has the following unique features. Please read carefully the Challenge-Specific Agreement.

  • Solvers are asked to prepare the compound and perform binding affinity assays to glucose in aqueous solution under conditions described in the Challenge Description. The compounds must also be supplied to Novo Nordisk in sufficient amounts to reproduce the results. Upon experimental validation of the results, Novo Nordisk will make an award (‘Initial Transfer Fee’) of $200,000 to the best solution as solely determined by the Seeker, according to the Challenge requirements. The Awarded Solver grants Novo Nordisk an exclusive license under the terms described in the Challenge-Specific Agreement.
  • Additionally, Novo Nordisk will offer a milestone-based agreement to the Solver, establishing the terms of payment of an additional award (‘Secondary Award’), should the small molecule be successful in its development post-Challenge (‘Second Evaluation Period’), in exchange for the assignment of exclusive IP rights to the Seeker.
Overview

Designing good carbohydrate receptors/binders working in aqueous systems remains a great challenge in chemical biology, but one with great implications due to the biological importance of carbohydrates. Glucose levels, particularly, have a role in many disease states, such as diabetes.  Therefore, molecules that selectively and reversibly bind to glucose are of great interest for therapeutic purposes. 

For this Challenge, Novo Nordisk invites Solvers to design and prepare in pure form a new small molecule that binds to D-glucose in water at neutral pH with affinity stronger than 100 (association constant, Ka), which equals a displacement constant (Kd) of 10 mM or lower. The Seeker is interested in molecules of molecular weight below 2,000 Daltons of any molecular class, except for a few exceptions detailed in the Challenge Description. 

This is a Reduction-to-Practice Challenge that requires written documentation, experimental proof-of-concept data, and sample delivery. Additionally, the Challenge has the following unique features. Please read carefully the Challenge-Specific Agreement.

  • Solvers are asked to prepare the compound and perform binding affinity assays to glucose in aqueous solution under conditions described in the Challenge Description. The compounds must also be supplied to Novo Nordisk in sufficient amounts to reproduce the results. Upon experimental validation of the results, Novo Nordisk will make an award (‘Initial Transfer Fee’) of $200,000 to the best solution as solely determined by the Seeker, according to the Challenge requirements. The Awarded Solver grants Novo Nordisk an exclusive license under the terms described in the Challenge-Specific Agreement.
  • Additionally,  Novo Nordisk will offer a milestone-based agreement to the Solver, establishing the terms of payment of an additional award (‘Secondary Award’), should the small molecule be successful in its development post-Challenge (‘Second Evaluation Period’), in exchange for the assignment of exclusive IP rights to the Seeker

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on January 9, 2017. Late submissions may not be considered.

About the Seeker

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40.000 people in 75 countries, and markets its products in more than 180 countries.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is an RTP Challenge?

An InnoCentive RTP (Reduction to Practice) Challenge is a prototype that proves an idea, and is similar to an InnoCentive Theoretical Challenge in its high level of detail. However, an RTP requires the Solver to submit a validated solution, either in the form of original data or a physical sample. Also the Seeker is allowed to test the proposed solution. For details about treatment of IP rights, please see the Challenge-Specific Agreement.

Share This Challenge
InnoCentive Trust Partners